SEC Tracker
Get the app

Neogenomics NEO

Neogenomics FY 2023: net loss $88.0M

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Neogenomics reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Net income−$88.0MAgainst −$144.3M in FY 202210-K income statement, on EDGAR
  2. Cash and cash equivalents$342.5M+30% from $263.2M in FY 202210-K balance sheet, on EDGAR
  3. Cash from operations−$2.0MAgainst −$66.0M in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Neogenomics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8734 and related industry codes: the same peer list as the financial tables.

  1. Absci ABSI public float $304M, Jun 30, 2025
  2. Maxcyte MXCT public float $231M, Jun 30, 2025
  3. NRC Health NRC public float $195M, Jun 30, 2025
  4. OmniAb OABI public float $145M, Jun 30, 2025